Brought to you by 
Merck becomes Arvinas' first partner for new PROTAC-based drugs
01 Feb 2023
Executive Summary
Two-year old Arvinas LLC penned its first major agreement, signing a multi-year deal with Merck & Co. Inc. to use the PROTAC protein degradation technology against targets selected by Merck. While Arvinas’ focus up until now has been using the platform for cancer, the companies note that several undisclosed therapy areas will be involved.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck becomes Arvinas' first partner for new PROTAC-based drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice